Mablink Bioscience to Present Promising Preclinical Data

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023

  • In vivo antitumor efficacy with significant tumor growth inhibition in multiple models with varying levels of FOLR1 expression
  • Highly promising safety results in non-human primates, enabling a broad therapeutic window
  • High conjugation yields, along with 100% DAR8 homogeneity and stability, major drivers of the successful ongoing manufacturing process
  • IND submission planned in Q4 2023

Lyon - France, March 14, 2023 (22h30 CET)

Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates (ADCs), today announced that preclinical efficacy and safety data on its lead ADC candidate, MBK-103, will be presented at the American Association for Cancer Research (“AACR“) Meeting 2023 on April 17, 2023, in Orlando, Florida.

Mablink's poster will include in vivo efficacy data in mouse models and safety data in non-human primates (see abstract).

Mablink presented the proof-of-concept results it obtained with its proprietary ADC platform PSARLink™ in previous scientific articles and posters. PSARLink™ ADCs present an enhanced hydrophilicity and plasma-stability which translates into an improved tolerability and a prolonged half-life, similar to the unconjugated antibody. The increased drug-exposure in rodent models correlates with an improved anti-tumoral efficacy.

MBK-103 is the first development candidate coming from the PSARLink™ platform and it confirms the pharmacological improvement observed in the PoC experiments.

MBK-103, an antibody-drug conjugate targeting the Folate receptor alpha (FOLR1 or FRα), demonstrated excellent ex vivo stability in human plasma, which should lead to a lower off-target toxicity.
Significant tumor growth inhibition was achieved in more than 10 in vivo mouse tumor models at low doses (1-3 mg/kg) with varying levels of FRα expression. The distinct mode of action of exatecan (anti-topo-I, the payload) and the unique characteristics of the proprietary drug-linker platform resulted in potent anti-tumor efficacy obtained notably in colorectal cancer, where tubulin inhibitors have shown poor therapeutic efficacy.
The compound was also well tolerated in cynomolgus monkeys at the highest non-severely toxic dose (HNSTD) of 50 mg/kg administered repeatedly. These promising data are a significant differentiator in the ADC’s landscape.
High conjugation yields along with 100% homogeneity are key drivers of the successful ongoing manufacturing process in preparation of initiating clinical trials, since Mablink plans to submit a Clinical Trial Application (CTA)in the fourth quarter of 2023.

“We are excited about MBK-103 as a new generation ADC therapeutic candidate driven by a promising therapeutic index,” said Jean-Guillaume Lafay, CEO of Mablink, “Our ongoing IND-enabling study program to support first-in-human trials with MBK-103 is delivering as expected and we plan to submit our CTA in the fourth quarter of 2023.

Details about the poster presentation

Title: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients

Poster Board number: 24
Abstract Presentation Number: 1544
Presenter: Lenka Kyrych Sadilkova, PhD
Session category: Experimental and Molecular Therapeutics
Session title: Antibody Drug Conjugates
Session date and time: Monday Apr 17, 2023, 9:00 AM - 12:30 PM

About Mablink Bioscience

Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLinkTM, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability.

For more information, please visit https://mablink.com

About MBK-103

MBK-103, an antibody-drug conjugate targeting the Folate receptor alpha (FOLR1 or FRα), is based on Mablink’s PSARLinkTM proprietary hydrophilic drug-linker platform. It consists of: (i) an Fc-attenuated humanized IgG1 monoclonal antibody, that binds selectively to FRα; (ii) a polysarcosine hydrophobicity masking entity that allows for a high drug-antibody-ratio (DAR) of 8, while improving the pharmacokinetics and tolerability of the drug; (iii) a proprietary dipeptide cleavable unit and (iv) exatecan, a potent topoisomerase I inhibitor as the payload.

FRα is a clinically validated target, that is overexpressed extracellularly in numerous solid tumors with high unmet medical need. Ovarian, non-small cell lung and breast adenocarcinoma are among the indications with the highest frequency of FRα-positive patients with every second patient showing upregulated topoisomerase I expression.



Mablink Bioscience to Present Promising Preclinical Data

TIN LIÊN QUAN

Tango Therapeutics to Highlight Preclinical Data on

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...

Sana Biotechnology Announces the Acceptance of Four

Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene...

Small Pharma to Host Virtual Roundtable Event with Key

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company...

Notice of the Annual General Meeting 2023 of Copenhagen

Notice is hereby given of the Annual General Meeting of Copenhagen Airports A/S to be held on Thursday, 30 March 2023 at 3:00 pm. The notice, including...

AIM ImmunoTech to Participate in Solve M.E. and The

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all...

05/2023 Green Hydrogen Systems announces changes to its

Company announcement 05/2023 Green Hydrogen Systems announces changes to its Board of Directors Kolding, Denmark, 1 March 2023 – In connection with...

THỦ THUẬT HAY

Hướng dẫn bạn cách sửa lỗi 0x80070643 trên Windows 11

Người dùng Windows 11 mới đây cho biết, họ gặp phải lỗi cập nhật 0x80070643 khi cài đặt các bản cập nhật vá lỗi mới thông qua Settings. Nếu gặp phải trường hợp đó, hãy khắc phục theo một trong các cách dưới đây.

Tắt các chức năng không cần thiết trên iOS tiêu tốn lượng pin đáng kể

Dung lượng pin trên các máy iPhone đã hạn chế rất nhiều so với các điện thoại Android khác. Đồng thời nếu bạn không thể sở hữu được chiếc iPhone Plus để có dung lượng pin lớn thì việc chiếc iPhone tắt giữa chừng khi

Cách thêm hoặc loại bỏ các tính năng tùy chọn trong Windows 11

Nếu bạn cảm thấy Windows 11 hơi thiếu hoặc thừa các tính năng so với Windows 10 thì dưới đây là cách để bật/tắt một số tính năng khác mà bạn muốn.

Mẹo hay giúp MacBook hoặc iMac có thể nhận cuộc gọi từ iPhone

Có thể bạn chưa biết, Apple đã trang bị cho hệ điều hành macOS tính năng giúp MacBook hoặc iMac có thể nhận cuộc gọi từ iPhone.

Mẹo hay biến iPhone thành webcam của laptop

Đã bao giờ bạn nghĩ đến chuyện tận dụng camera độ phân giải cao của iPhone thay cho webcam chất lượng dở tệ trên laptop. Bạn có thể sử dụng ứng dụng miễn phí iVCam để làm được điều này. Về cơ chế hoạt động, iVCam giúp

ĐÁNH GIÁ NHANH

Đánh giá Vivo Y20s: nhiều ưu điểm vượt trội trong phân khúc 5 triệu

Thuộc phân khúc giá rẻ nhưng Vivo Y20s lại sở hữu nhiều tính năng vượt trội so với các mẫu smartphone cùng phân khúc giá. Để hiểu hơn về chiếc điện thoại này hãy xem giới chuyên môn đánh giá Vivo Y20s như thế nào nhé.

Đánh giá AMD Athlon X4 880K – "Bình mới rượu cũ"

Bên cạnh giải pháp tản nhiệt mới Wraith Cooler, AMD cũng chính thức bán ra thị trường loạt bộ xử lý mới vào đầu tháng Ba vừa qua. Trong đó phổ thông nhất là mẫu Athlon X4 845 có...